Scarica l'app Stockscreener
21.28
2.43%
-0.53
Dopo l'orario di chiusura:
21.28
Precedente Chiudi:
$21.81
Aprire:
$21.48
Volume 24 ore:
537.52K
Relative Volume:
0.65
Capitalizzazione di mercato:
$2.39B
Reddito:
$14.09M
Utile/perdita netta:
$-176.94M
Rapporto P/E:
-9.8977
EPS:
-2.15
Flusso di cassa netto:
$-141.24M
1 W Prestazione:
-9.83%
1M Prestazione:
+16.79%
6M Prestazione:
-4.53%
1 anno Prestazione:
+23.33%
Intervallo 1D:
$21.14
$22.01
Intervallo di 1 settimana:
$21.14
$24.18
Portata 52W:
$14.06
$27.29
Newamsterdam Pharma Company Nv Stock (NAMS) Company Profile
Nome
Newamsterdam Pharma Company Nv
Settore
Industria
Telefono
35 206 2971
Indirizzo
GOOIMEER 2-35, NARRDEN
Confronta NAMS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NAMS
Newamsterdam Pharma Company Nv
|
21.28 | 2.45B | 14.09M | -176.94M | -141.24M | -2.15 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Newamsterdam Pharma Company Nv Stock (NAMS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-17 | Iniziato | Goldman | Neutral |
| 2025-06-17 | Iniziato | Citigroup | Buy |
| 2025-06-10 | Iniziato | Stifel | Buy |
| 2025-06-04 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-12-30 | Iniziato | H.C. Wainwright | Buy |
| 2024-05-15 | Iniziato | TD Cowen | Buy |
| 2024-03-14 | Iniziato | Scotiabank | Sector Outperform |
| 2024-01-18 | Iniziato | Guggenheim | Buy |
| 2024-01-16 | Iniziato | Piper Sandler | Overweight |
| 2023-10-30 | Iniziato | RBC Capital Mkts | Outperform |
Mostra tutto
Newamsterdam Pharma Company Nv Borsa (NAMS) Ultime notizie
Is NewAmsterdam Pharma Company N.V. Equity Warrant a growth stock or a value stockAdvanced Screener Alerts That Work - jammulinksnews.com
When is NewAmsterdam Pharma Company N.V. stock expected to show significant growthAI Powered Tips For 2025 - jammulinksnews.com
What are NewAmsterdam Pharma Company N.V. Equity Warrant company’s key revenue driversPre Market Trend Scanner From AI Tools - jammulinksnews.com
What are analysts’ price targets for NewAmsterdam Pharma Company N.V. in the next 12 monthsPre Market Entry Points To Watch Now - jammulinksnews.com
Why is NewAmsterdam Pharma Company N.V. Equity Warrant stock attracting strong analyst attentionValue Investing Guidance To Watch Now - jammulinksnews.com
What is NewAmsterdam Pharma Company N.V. company’s growth strategySwing Trade Forecasts For Smart Trading - jammulinksnews.com
Does NewAmsterdam Pharma Company N.V. qualify in momentum factor screeningReal-Time Analysis With Entry Targets In Progress - metal.it
What institutional investors are buying NewAmsterdam Pharma Company N.V. stockRetirement Planning Guidance To Watch Now - jammulinksnews.com
Transcript : NewAmsterdam Pharma Company N.V.Special Call - MarketScreener
Can NewAmsterdam Pharma Company N.V. recover in the next quarterDaily Growth Stock Pick Reports Show Bullish Signals - metal.it
In Broadway trial, a hopeful tune for Alzheimer’s prevention - BioWorld MedTech
NewAmsterdam Pharma Company N.V. Presents Positive Data from Br Broadway Trial Demonstrating Statistically Significant Reductions in Key Alzheimer's Disease Biomarkers At Aaic 2025 - MarketScreener
Will NewAmsterdam Pharma Company N.V. Reverse From Oversold ConditionsReal-Time Trade Insights Spark Market Reactions - metal.it
NewAmsterdam Pharma Presents Positive Data from BROADWAY - GlobeNewswire
Frazier Lifesciences Acquisition : NewAmsterdam Pharma Alzheimers Analysis (1) - MarketScreener
NewAmsterdam Pharma’s Promising Phase 3 Alzheimer’s Trial Results - TipRanks
Breakthrough: NewAmsterdam's Obicetrapib Shows Major Alzheimer's Prevention Potential in Clinical Trial - Stock Titan
Published on: 2025-07-29 22:25:06 - metal.it
NewAmsterdam Pharma Company N.V. Equity Warrant Outperforms Peers on Volume MetricsTriple Digit Return Stock Predictions Released - metal.it
What are the technical indicators suggesting about NewAmsterdam Pharma Company N.V. Equity WarrantStock Strategy Entry Points Backed By Experts - jammulinksnews.com
What institutional investors are buying NewAmsterdam Pharma Company N.V. Equity Warrant stockExpert Picks Watchlist For 2025 - jammulinksnews.com
NewAmsterdam Pharma Company N.V. Stock Performance After Earnings: Historical InsightsInsider Level Guidance - metal.it
What are the technical indicators suggesting about NewAmsterdam Pharma Company N.V.Free Consultation - jammulinksnews.com
Why is NewAmsterdam Pharma Company N.V. stock attracting strong analyst attentionUnstoppable profit momentum - jammulinksnews.com
What makes NewAmsterdam Pharma Company N.V. Equity Warrant stock price move sharplyFree Daily Trading Room Entry - jammulinksnews.com
How strong is NewAmsterdam Pharma Company N.V. Equity Warrant company’s balance sheetFree Stock Market Trend Analysis - jammulinksnews.com
Should I hold or sell NewAmsterdam Pharma Company N.V. Equity Warrant stock in 2025Retirement Planning Guidance To Watch Now - jammulinksnews.com
What are NewAmsterdam Pharma Company N.V. company’s key revenue driversAchieve breakthrough financial results - jammulinksnews.com
Should I hold or sell NewAmsterdam Pharma Company N.V. stock in 2025Capitalize on stocks with high profit margins - jammulinksnews.com
What are the latest earnings results for NewAmsterdam Pharma Company N.V. Equity WarrantPhenomenal wealth increase - jammulinksnews.com
What is the dividend policy of NewAmsterdam Pharma Company N.V. stockUnlock exclusive trading strategies for gains - jammulinksnews.com
How strong is NewAmsterdam Pharma Company N.V. company’s balance sheetPhenomenal investment performance - jammulinksnews.com
What catalysts could drive NewAmsterdam Pharma Company N.V. Equity Warrant stock higher in 2025Extraordinary market timing - jammulinksnews.com
Published on: 2025-07-27 21:05:32 - jammulinksnews.com
Published on: 2025-07-27 20:54:33 - jammulinksnews.com
How NewAmsterdam Pharma Company N.V. Equity Warrant stock performs during market volatilityFree Predictions - Newser
What are the latest earnings results for NewAmsterdam Pharma Company N.V.Achieve rapid portfolio appreciation today - jammulinksnews.com
Is NewAmsterdam Pharma Company N.V. Equity Warrant a Top Dividend Stock to Watch in 2025Free Stock Trading Signals - Newser
Top Risks to Consider Before Buying NewAmsterdam Pharma Company N.V. StockBreakout Level Watch - Newser
Why NewAmsterdam Pharma Company N.V. Equity Warrant stock attracts strong analyst attentionFree Predictions - Newser
Newamsterdam Pharma Company Nv Azioni (NAMS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Newamsterdam Pharma Company Nv Azioni (NAMS) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Kling Douglas F | Chief Operating Officer |
Jul 15 '25 |
Option Exercise |
10.90 |
47,569 |
518,502 |
91,569 |
| Kling Douglas F | Chief Operating Officer |
Jul 16 '25 |
Sale |
21.10 |
51,043 |
1,077,007 |
44,000 |
| Kling Douglas F | Chief Operating Officer |
Jul 15 '25 |
Sale |
21.44 |
47,569 |
1,019,648 |
44,000 |
0.93%
0.15%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):